1.    Malik PR, Yeung CH, Ismaeil S, Advani U, Djie S, Edginton AN. A physiological approach to pharmacokinetics in chronic kidney disease. The Journal of Clinical Pharmacology. 2020 Nov;60:S52-62.
2. Willmann S, Hohn K, Edginton A, et al. Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007;34(3):401-31.
3. Vegar Zubovic S, Kristic S, Sefic Pasic I. Relationship be-tween ultrasonographically determined kidney volume and progression of chronic kidney disease. Med Glas (Zenica). 2016;13(2):90-94
4. Jovanovic D, Gasic B, Pavlovic S, Naumovic R. Correlation of kidney size with kidney function and anthropometric parameters in healthy subjects and patients with chronic kidney diseases. Ren Fail. 2013;35(6):896-900.
5. Kim HC, Yang DM, Jin W, Lee SH. Relation between total renal volume and renal function: usefulness of 3D sonographic measurements with a matrix array transducer. AJR Am J Roentgenol. 2010;194(2):W186-192.
6. Buchanan CE, Mahmoud H, Cox EF, et al. Quantitative assessment of renal structural and functional changes in chronic kidney disease using multi-parametric magnetic resonance imaging. Nephrol Dial Transplant. 2020;35(6):955-964.
7. Gillis KA, McComb C, Patel RK, et al. Non-contrast renal magnetic resonance imaging to assess perfusion and corticomedullary differentiation in health and chronic kidney disease. Nephron. 2016;133(3):183-192.
8. Rossi C, Artunc F, Martirosian P, Schlemmer HP, Schick F, Boss A. Histogram analysis of renal arterial spin labeling per-fusion data reveals differences between volunteers and patients with mild chronic kidney disease. Invest Radiol. 2012;47(8):490-496.
9.  Hsu C-Y, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001;59(2):725-731.
10. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10(6):1309-1316.
11. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10(3):610-619.
12. Tan ML, Yoshida K, Zhao P, et al. Effect of chronic kidney dis-ease on nonrenal elimination pathways: a systematic assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP. Clin Pharmacol Ther. 2018;103(5):854-867.
13. Hirako M, Kamiya T, Misu N, et al. Impaired gastric motility and its relationship to gastrointestinal symptoms in patients with chronic renal failure. J Gastroenterol. 2005;40(12):1116.
14. Fu R-G, Wang Y, Yuan H-Z, et al. Effects of chronic renal failure on gastrointestinal motility: a study on the changes of gastric emptying, small intestinal transit, interdigestive myoelectric complex, and fecal water content. Ren Fail. 2011;33(6):615-621.
15. Guz G, Bali M, Poyraz NY, et al. Gastric emptying in patients on renal replacement therapy. Ren Fail. 2004;26(6):619-624.
16. De Schoenmakere G, Vanholder R, Rottey S, Duym P, Lameire N. Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients. Nephrol Dial Transplant. 2001;16(9):1850-1855.
17. Van Vlem B, Schoonjans R, Vanholder R, et al. Delayed gastric emptying in dyspeptic chronic hemodialysis patients. Am J Kidney Dis. 2000;36(5):962-968.
18. Broberg B, Madsen JL, Fuglsang S, et al. Gastrointestinal motility in patients with end-stage renal disease on chronic hemodialysis. Neurogastroenterol Motil. 2019;31(4):e13554.
19. Hoibian E, Florens N, Koppe L, Vidal H, Soulage CO. Distal colon motor dysfunction in mice with chronic kidney disease: Putative role of uremic toxins. Toxins (Basel). 2018;10(5):204.
20. Wu MJ, Chang CS, Cheng CH, et al. Colonic transit time in long-term dialysis patients. Am J Kidne Dis. 2004;44(2):322-327.
21.  Pfizer. Neurontin (Gabapentin) Label. 2017.
22.  Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010;49(10):661-9.
23.  Vollmer KO, von Hodenberg A, Kolle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneimittelforschung. 1986;36(5):830-9.
24.  Urban TJ, Brown C, Castro RA, et al. Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin Pharmacol Ther. 2008;83(3):416-21.
25.  PubChem. Gabapentin. https://pubchem.ncbi.nlm.nih.gov/compound/Gabapentin. 
26.  Madan J, Chawla G, Arora V, Malik R, Bansal AK. Unbiased membrane permeability parameters for gabapentin using boundary layer approach. AAPS J. 2005;7(1):E224-30.
27.  Kasim NA, Whitehouse M, Ramachandran C, et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm. 2004;1(1):85-96.
28.  Raouf M, Atkinson TJ, Crumb MW, Fudin J. Rational dosing of gabapentin and pregabalin in chronic kidney disease. J Pain Res. 2017;10:275-8.
29.  Gidal BE, Radulovic LL, Kruger S, Rutecki P, Pitterle M, Bockbrader HN. Inter- and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res. 2000;40(2-3):123-7.
30. Gidal BE, DeCerce J, Bockbrader HN, et al. Gabapentin bioavailability: effect of dose and frequency of administration in adult patients with epilepsy. Epilepsy Res. 1998;31(2):91-9.
31. Dickens D, Webb SD, Antonyuk S, et al. Transport of gabapentin by LAT1 (SLC7A5). Biochem Pharmacol. 2013;85(11):1672-83.
32. Boyd RA, Turck D, Abel RB, Sedman AJ, Bockbrader HN. Effects of age and gender on single-dose pharmacokinetics of gabapentin. Epilepsia. 1999;40(4):474-9.
33. Tjandrawinata RR, Setiawati E, Putri RS, Yunaidi DA, Amalia F, Susanto LW. Single dose pharmacokinetic equivalence study of two gabapentin preparations in healthy subjects. Drug Des Devel Ther. 2014;8:1249-55.
34.   Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther. 1994;56(2):154-159.
35.  Reddy Pharmaceuticals. Sectral (Acebutolol Hydrochloride) Label. 2007.
36.  Muta K, Fukami T, Nakajima M. A proposed mechanism for the adverse effects of acebutolol: CES2 and CYP2C19-mediated metabolism and antinuclear antibody production. Biochem Pharmacol. 2015;98(4):659-70.
37.  Roux A, Aubert P, Guedon J, Flouvat B. Pharmacokinetics of acebutolol in patients with all grades of renal failure. Eur J Clin Pharmacol. 1980;17(5):339-48.
38.  DrugBank. Acebutolol. https://www.drugbank.ca/drugs/DB01193. 
39.  Taylor DC, Pownall R, Burke W. The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity. J Pharm Pharmacol. 1985;37(4):280-3.
40.  Coombs TJ, Coulson CJ, Smith VJ. Blood plasma binding of acebutolol and diacetolol in man. B J Clin Pharmacol. 1980;9(4):395-7.
41.  Foster RJ, Carr RA. Acebutolol. In: Florey K, ed. Analytical Profiles of Drug Substances. Vol 19. Academic Press; 1990:1-26.
42.  Roux A, Flouvat B, Fouache Y, Bourdarias JP. Systemic bioavailability of acebutolol in man. Biopharm Drug Dispos. 1983;4(3):293-7.
43.  Gulaid AA, James IM, Kaye CM, et al. The pharmacokinetics of acebutolol in man, following the oral administration of acebutolol HCl as a single dose (400 mg), and during and after repeated oral dosing (400 mg, b.d.). Biopharm Drug Dispos. 1981;2(2):103-14.
44. Roux A, Le Liboux A, Delhotal B, Gaillot J, Flouvat B. Pharmacokinetics in man of acebutolol and hydrochlorothiazide as single agents and in combination. Eur J Clin Pharmacol. 1983;24(6):801-6.
45. Roux A, Henry JF, Fouache Y, et al. A pharmacokinetic study of acebutolol in aged subjects as compared to young subjects. Gerontology. 1983;29(3):202-8.
46. Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007;35(4):590-4.
47. Basit A, Radi Z, Vaidya VS, Karasu M, Prasad B. Kidney cortical transporter expression across species using quantitative proteomics. Drug Metab Dispos. 2019;47(8):802-8.
48.  DrugBank. Atenolol. https://www.drugbank.ca/drugs/DB00335.
49.  Kirch W, Görg K. Clinical pharmacokinetics of atenolol—a review. Eur J Drug Metab Pharmacokinet. 1982;7(2):81-91.
50.  Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825-92.
51.  Yin J, Duan H, Shirasaka Y, Prasad B, Wang J. Atenolol renal secretion is mediated by human organic cation transporter 2 and multidrug and toxin extrusion proteins. Drug Metab Dispos. 2015;43(12):1872-81.
52.  Colin Brown H, George Carruthers S, Dennis Johnston G, et al. Clinical pharmacologic observations on atenolol, a beta‐adrenoceptor blocker. Clin Pharmacol Ther. 1976;20(5):524-34.
53.  Kirch W, Schafer M, Braun M. Single intravenous dose kinetics accumulation of atenolol in patients with impaired renal function and on hemodialysis. Arch Toxicol Suppl. 1980;4:366-9.
54.  Kirch W, Köhler H, Mutschler E, Schäfer M. Pharmacokinetics of atenolol in relation to renal function. Eur J Clin Pharmacol. 1981;19(1):65-71.
55.  Mason WD, Winer N, Kochak G, Cohen I, Bell R. Kinetics and absolute bioavailability of atenolol. Clin Pharmacol Ther. 1979;25(4):408-15.
56.  Wan S, Koda R, Maronde R. Pharmacokinetics, pharmacology of atenolol and effect of renal disease. Br J Clin Pharmacol. 1979;7(6):569-74.
57. Moneghini M, Carcano A, Zingone G, Perissutti B. Studies in dissolution enhancement of atenolol. Part I. Int J Pharmaceutics. 1998;175(2):177-83.
58. Taylor DC, Grundy R, Loveday B. Chronic dog intestinal loop model for studying drug absorption as exemplified by β-adrenoreceptor blocking agents, atenolol and propranolol. J Pharm Sci. 1981;70(5):516-21.
59. Taylor DC, Pownall R, Burke W. The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity. J Pharm Pharmacol. 1985;37(4):280-3.
60. Dobson CL, Davis SS, Chauhan S, Sparrow RA, Wilding IR. The effect of ileal brake activators on the oral bioavailability of atenolol in man. Int J Pharmaceutics. 2002;248(1-2):61-70.
61. Schipper NG, Vårum KM, Stenberg P, Ocklind G, Lennernäs H, Artursson P. Chitosans as absorption enhancers of poorly absorbable drugs. 3: Influence of mucus on absorption enhancement. Eur J Pharm Sci. 1999;8(4):335-43.
62. Murakami T. Absorption sites of orally administered drugs in the small intestine. Expert Opin Drug Discov. 2017;12(12):1219-32.
63. Mimura Y, Yasujima T, Ohta K, Inoue K, Yuasa H. Functional identification of Plasma Membrane Monoamine Transporter (PMAT/SLC29A4) as an atenolol transporter sensitive to flavonoids contained in apple juice. J Pharm Sci. 2017;106(9):2592-98.
64. Conway F, Fitzgerald J, McAinsh J, Rowlands D, Simpson W. Human pharmacokinetic and pharmacodynamic studies on the atenolol (ICI 66,082), a new cardioselective beta‐adrenoceptor blocking drug. Br J Clin Pharmacol. 1976;3(2):267-72.
65. Frost C, Song Y, Yu Z, et al. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. Clin Pharmacol. 2017;9:19-28.
66. Sassard J, Pozet N, McAinsh J, Legheand J, Zech P. Pharmacokinetics of atenolol in patients with renal impairment. Eur J Clin Pharmacol. 1977;12(3):175-80.
67. Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007;35(4):590-4.
68. Basit A, Radi Z, Vaidya VS, Karasu M, Prasad B. Kidney cortical transporter expression across species using quantitative proteomics. Drug Metab Dispos. 2019;47(8):802-8.
69.  Sandoz Canada Inc. Gentamicin Injection USP. 2017. https://www.sandoz.ca/sites/www.sandoz.ca/files/Gentamicin%20Inj%20Product%20Monograph.pdf.
70.  APP Fresenius Kabi USA. Gentamicin Injection USP. 2013. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/062366s033lbl.pdf.
71.  Regamey C, Gordon RC, Kirby WMM. Comparative pharmacokinetics of tobramycin and gentamicin. Clin Pharmacol Ther. 1973;14(3):396-403.
72.  DrugBank. Gentamicin. https://www.drugbank.ca/drugs/DB00798.
73.  PubChem. Gentamicin. https://pubchem.ncbi.nlm.nih.gov/compound/Gentamicin.
74.  Dagil R, O'Shea C, Nykjaer A, Bonvin AM, Kragelund BB. Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats: insight from the nmr structure of the 10th complement type repeat domain alone and in complex with gentamicin. J Biol Chem. 2013;288(6):4424-35.
75.  Gyselynck AM, Forrey A, Cutler R. Pharmacokinetics of gentamicin: distribution and plasma and renal clearance. J Infect Dis. 1971;124 Suppl:S70-6.
76.  Davey PG, Geddes AM, Gonda I, Harpur ES, Scott DK. Comparison of methods for estimating gentamicin clearance and retrospective analysis of changes in clearance with emphasis on patients with normal renal function. Br J Clin Pharmacol. 1984;17(2):147-55.
77.  Dume T, Wetzels E, Herms W, Schröder E, Wahlig H. Zur Pharmakokinetik von Gentamycinsulfat bei Gesunden und Patienten mit terminaler Niereninsuffizienz. Dtsch med Wochenschr. 1971;96(17):734-41.
78. Lorentzen H, Kallehave F, Kolmos HJ, Knigge U, Bulow J, Gottrup F. Gentamicin concentrations in human subcutaneous tissue. Antimicrob Agents Chemother. 1996;40(8):1785-9.
79. Meunier F, Van der Auwera P, Schmitt H, de Maertelaer V, Klastersky J. Pharmacokinetics of gentamicin after i.v. infusion or iv bolus. J Antimicrob Chemother. 1987;19(2):225-31.
80.   Ervin FR, Bullock WE, Jr., Nuttall CE. Inactivation of gentamicin by penicillins in patients with renal failure. Antimicrob Agents Chemother. 1976;9(6):1004-1011.
81.  DrugBank. Pindolol. https://www.drugbank.ca/drugs/DB00960.
82.  Hsyu P-H, Giacomini KM. Stereoselective renal clearance of pindolol in humans. J Clin Invest. 1985;76(5):1720-6.
83.  Cheung SYA, Rodgers T, Aarons L, et al. Whole body physiologically based modelling of β-blockers in the rat: events in tissues and plasma following an i.v. bolus dose. Br J Pharmacol. 2018;175(1):67-83.
84.  Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825-92.
85.  Galeazzi RL, Gugger M, Weidmann P. Beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man. Kidney Int. 1979;15(6):661-8.
86.  Guerret M, Cheymol G, Aubry J, Cheymol A, Lavene D, Kiechel J. Estimation of the absolute oral bioavailability of pindolol by two analytical methods. Eur J Clin Pharmacol. 1983;25(3):357-9.
87.  Lavene D, Weiss Y, Safar M, et al. Pharmacokinetics and hepatic extraction ratio of pindolol in hypertensive patients with normal and impaired renal function. J Clin Pharmacol. 1977;17(8-9):501-8.
88.  Sakurada W, Shimoyama T, Itoh K, Kobayashi M. Solubility estimation for drugs treated with the simple suspension method using available dissolution test profiles. Iryo Yakugaku. 2015;41(8):540-9.
89.  Aellig W, Nüesch E, Pacha W. Pharmacokinetic comparison of pindolol 30 mg retard and 15 mg normal tablets. Eur J Clin Pharmacol. 1982;21(6):451-5.
90. Balant L, Muir K, Dayer P, et al. Simultaneous tubular excretion and reabsorption of pindolol in man. Eur J Clin Pharmacol. 1981;21(1):65-72.
91. Gretzer I, Alvan G, Duner H, Garle M, Sjöqvist F. Beta-blocking effect and pharmacokinetics of pindolol in young and elderly hypertensive patients. Eur J Clin Pharmacol. 1986;31(4):415-8.
92. Basit A, Radi Z, Vaidya VS, Karasu M, Prasad B. Kidney cortical transporter expression across species using quantitative proteomics. Drug Metab Dispos. 2019;47(8):802-8.
93.  Hanyok JJ. Clinical pharmacokinetics of sotalol. Am J Cardiol. 1993;72(4):19a-26a.
94.  Ivanyuk A, Livio F, Biollaz J, Buclin T. Renal drug transporters and drug interactions. Clin Pharmacokinet. 2017;56(8):825-92.
95.  Yang Y, Faustino PJ, Volpe DA, Ellison CD, Lyon RC, Yu LX. Biopharmaceutics classification of selected β-blockers: solubility and permeability class membership. Mol Pharm. 2007;4(4):608-14.
96.  Belpaire FM, Bogaert MG, Rosseneu M. Binding of β-adrenoceptor blocking drugs to human serum albumin, to α1-acid glycoprotein and to human serum. Eur J Clin Pharmacol. 1982;22(3):253-6.
97.  Shalaeva M, Kenseth J, Lombardo F, Bastin AJJops. Measurement of dissociation constants (pKa values) of organic compounds by multiplexed capillary electrophoresis using aqueous and cosolvent buffers. 2008;97(7):2581-606.
98.  Hancu G, Samarghitan C, Rusu A, Mircia E. Sotalol chiral separation by capillary electrophoresis. J Chil Chem Soc. 2014;59(3):2559-62.
99.  DrugBank. Sotalol. https://www.drugbank.ca/drugs/DB00489.
100. Misaka S, Knop J, Singer K, et al. The nonmetabolized beta-blocker nadolol is a substrate of OCT1, OCT2, MATE1, MATE2-K, and p-glycoprotein, but not of OATP1B1 and OATP1B3. Mol Pharm. 2016;13(2):512-19.
101. Anttila M, Arstila M, Pfeffer M, Tikkanen R, Vallinkoski V, Sundquist H. Human pharmacokinetics of sotalol. Acta Pharmacol Toxicol (Copenh). 1976;39(1):118-28.
102.   Poirier JM, Jaillon P, Lecocq B, Lecocq V, Ferry A, Cheymol G. The pharmacokinetics of d-sotalol and d,l-sotalol in healthy volunteers. Eur J Clin Pharmacol. 1990;38(6):579-82.
103.   Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH. A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol. 2013;37(9):799-809.
104.   Uematsu T, Kanamaru M, Nakashima M. Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)‐sotalol in healthy volunteers. J Pharm Pharmacol. 1994;46(7):600-605.
105.   Dahan A, Lennernäs H, Amidon GL. The fraction dose absorbed, in humans, and high jejunal human permeability relationship. Mol Pharm. 2012;9(6):1847-51.
106.   Murakami T. Absorption sites of orally administered drugs in the small intestine. Expert Opin Drug Discov. 2017;12(12):1219-32.
107.   Taylor DC, Pownall R, Burke W. The absorption of beta-adrenoceptor antagonists in rat in-situ small intestine; the effect of lipophilicity. J Pharm Pharmacol. 1985;37(4):280-3.
108.   Tjandramaga TB, Verbeeck R, Thomas J, Verbesselt R, Verberckmoes R, Schepper PJ. The effect of end-stage renal failure and haemodialysis on the elimination kinetics of sotalol. Br J Clin Pharmacol. 1976;3(2):259-65.
109.   Meier Y, Eloranta JJ, Darimont J, et al. Regional distribution of solute carrier mRNA expression along the human intestinal tract. Drug Metab Dispos. 2007;35(4):590-4.
110.   Basit A, Radi Z, Vaidya VS, Karasu M, Prasad B. Kidney cortical transporter expression across species using quantitative proteomics. Drug Metab Dispos. 2019;47(8):802-8.
111. ANI Pharmaceuticals Inc. Vancomycin Hydrochloride for Injection USP. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/060180s048lbl.pdf.
112. Chen Y, Norris RL, Schneider JJ, Ravenscroft PJ. The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J Pharmacol Toxicol Methods. 1992;28(1):57-60.
113. Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986;11(4):257-82.
114. Radke C, Horn D, Lanckohr C, et al. Development of a physiologically based pharmacokinetic modelling approach to predict the pharmacokinetics of vancomycin in critically ill septic patients. Clin Pharmacokinet. 2017;56(7):759-79.
115. DrugBank. Vancomycin. https://www.drugbank.ca/drugs/DB00512.
116. Krogstad DJ, Moellering Jr RC, Greenrlatt DJ. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980;20(4):197-201.
117. Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011;55(9):4277-82.
118. Vandecasteele SJ, De Vriese AS. Recent changes in vancomycin use in renal failure. Kidney Int. 2010;77(9):760-4.
119. Cutler NR, Narang PK, Lesko LJ, Ninos M, Power M. Vancomycin disposition: the importance of age. Clin Pharmacol Ther. 1984;36(6):803-10.
120.   Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother. 1982;21(4):575-80.
121.   Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ. Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother. 1987;31(3):393-7.
122.  Decker BS, Kays MB, Chambers M, Kraus MA, Moe SM, Sowinski KM. Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis. Clin J Am Soc Nephrol. 2010;5(11):1981-1987.
